Lipocine Says LPCN 1154 Met standard Bioequivalence (BE) Criteria; Co Says On Track For NDA Filing, Targeting Q4 2024
Portfolio Pulse from Benzinga Newsdesk
Lipocine announced that its drug LPCN 1154 met the standard bioequivalence criteria and was well tolerated with no sedation or somnolence events. The company is on track for an NDA filing, targeting Q4 2024.
June 25, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lipocine's LPCN 1154 met bioequivalence criteria and showed no sedation or somnolence. The company is on track for an NDA filing by Q4 2024.
Meeting bioequivalence criteria and showing no adverse events are positive indicators for LPCN 1154. The NDA filing timeline suggests progress in the drug's development, likely boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100